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ABSTRACT
The NETTER-1 trial demonstrated significantly improved progression-free 
survival (PFS) for peptide receptor radionuclide therapy (PRRT) in neuroendocrine 
tumors (NET) emphasizing the high demand for response prediction in appropriate 
candidates. In this multicenter study, we aimed to elucidate the prognostic value 
of tumor heterogeneity as assessed by somatostatin receptor (SSTR)-PET/CT. 141 
patients with SSTR-expressing tumors were analyzed obtaining SSTR-PET/CT before 
PRRT (1-6 cycles, 177Lu somatostatin analog). Using the Interview Fusion Workstation 
(Mediso), a total of 872 metastases were manually segmented. Conventional PET 
parameters as well as textural features representing intratumoral heterogeneity were 
computed. The prognostic ability for PFS and overall survival (OS) were examined. 
After performing Cox regression, independent parameters were determined by ROC 
analysis to obtain cut-off values to be used for Kaplan-Meier analysis. Within follow-up 
(median, 43.1 months), 75 patients showed disease progression (median, 22.2 m) and 
54 patients died (median, 27.6 m). Cox analysis identified 8 statistically independent 
heterogeneity parameters for time-to-progression and time-to-death. Among them, 
the textural feature Entropy predicted both PFS and OS. Conventional PET parameters 
failed in response prediction. Imaging-based heterogeneity assessment provides 
prognostic information in PRRT candidates and outperformed conventional PET 
parameters. Its implementation in clinical practice can pave the way for individualized 
patient management.
INTRODUCTION
Over the past decades, a rising incidence of 
neuroendocrine tumors (NET) has been reported [1]. With 
a delay in diagnosis of 5-7 years, NET typically present at 
advanced stages. In clinical routine, physicians often have 
to rely on single tumor biopsies for treatment decisions 
and might therefore be prone to sampling bias which 
ultimately leads to either misdiagnosis or underestimation 
of therapeutic response [2, 3]. Therefore, non-invasive, 
whole-body assessment of tumor heterogeneity 
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is highly desirable. Due to its ability to visualize 
functional alterations on a molecular level instead of 
pure morphological characteristics, positron emission 
tomography (PET) has proven its prognostic value in risk 
stratification for several types of cancer [4-6]. 
Recently, the NETTER-1 trial (ClinicalTrials.gov 
Identifier: NCT01578239) demonstrated significantly 
improved progression-free survival (PFS) for NET 
patients treated with the β-emitter labeled somatostatin 
analog 177Lu-DOTA-D-Phe-Tyr3-octreotate (DOTATATE) 
in advanced midgut NET [7-10]. Thus, rising numbers 
of peptide receptor radionuclide therapy (PRRT) can be 
expected in the next years.
As a prerequisite, pre-therapeutic somatostatin 
receptor (SSTR)-PET/computed tomography (CT) is 
mandatory to confirm adequate receptor density on the 
tumor cell surface [11, 12]. Consequently, the imaging 
agent 68Ga-DOTATATE was recently approved by the FDA 
which will also promote use of PRRT and simultaneously 
emphasizes the need for reliable response prediction prior 
to treatment initiation. 
In this present multi-center trial, we aimed to 
elucidate the prognostic capability of intratumoral 
heterogeneity parameters assessed by baseline SSTR-PET/
CT in patients scheduled for radionuclide therapy.
RESULTS
A total of 141 SSTR-PET scans were performed 
prior to PRRT. Baseline PET was positive in all patients 
as a prerequisite for treatment initiation. 120/141 (85.1%) 
subjects suffered from liver metastases, more than half of 
the cohort demonstrated lymph node metastases (78/141, 
55.3%), one third suffered from bone lesions (53/141, 
37.6%) and 16/141 (11.3%) demonstrated pulmonary 
metastases (Table 1).
Within follow-up (median, 43.1 months, range, 
22.3 - 89.8 m), 75/139 subjects (54.0%) experienced 
progressive disease. On average, progression was detected 
at a median of 22.2 m after the pre-therapeutic baseline 
PET scan (mean, 27.1 m, range, 4 days - 85.2 m). 54/141 
(38.3%) patients died from their cancer after a median 
of 27.6 m (mean, 31.4 m, range, 4 days - 85.2 m). The 
median proliferation index Ki67 in those patients was 5% 
(range, 1-40%). 
Correlation of clinical parameters with both PFS 
and OS
Cox regression analysis of clinical parameters (as 
given in Table 1) was performed. Regarding PFS and 
OS, cumulative dose was the only parameter reaching 
significance (PFS, p < 0.02, OS, p < 0.01). Moreover, 
Table 1: Detailed patients’ characteristics.
* = median and range is given, # = including meningeoma, hemangioendothelioma, pheochromocytoma, medullary thyroid 
carcinoma and pituitary tumor. GBq = Gigabecquerel, GEP-NET = gastroenteropancreatic neuroendocrine tumors, MBq = 
Megabecquerel, PRRT = Peptide Receptor Radionuclide Therapy, SSTR-PET/CT = somatostatin receptor positron emission 
tomography/computed tomography.
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several investigated clinical features trended to be 
significant (Ki67, PFS, p = 0.09; CgA, OS, p = 0.06).
Correlation of PET parameters with both PFS 
and OS
In Cox hazard analysis, the only parameter that 
showed significant correlation for both PFS (p = 0.02) and 
OS (p = 0.0002) was Entropy with Hazard Ratio (HR) of 
0.59 and 0.35, respectively. In addition, Skewness showed 
significant correlation (p = 0.04) with OS with an HR of 
0.58. 
In Receiver Operating Characteristics (ROC) 
analysis of the independent parameters Entropy, 
Correlation, Short Zone Emphasis and Homogeneity 
demonstrated significant prognostic ability for PFS. 
Significant prognostic values for OS were found for 
Entropy, Correlation, Homogeneity, Short Zone Emphasis 
and Size Variation. Of the investigated conventional 
PET parameters, Tissue Receptor Expression (TRE) 
was significant for OS (p = 0.003), whereas all other 
parameters failed in response prediction. Details can be 
found in Table 2 and selected ROC curves are shown in 
Supplementary Figure a.
Kaplan-Meier analysis using the threshold evaluated 
by ROC revealed a significant distinction between 
high- and low-risk patients for both PFS and OS for the 
following textural parameters: Entropy, Correlation, 
Short Zone Emphasis and Homogeneity. In addition, TRE 
showed a significant distinction for OS. Details including 
the negative and positive hazard ratios can be found in 
Table 3, respective Kaplan-Meier-plots for PFS are given 
in Figure 1 and for OS in Figure 2. An overview of the 
respective AUC values for both standard and heterogeneity 
PET parameters regarding PFS and OS are given in Table 
Table 2: Receiver Operating Characteristics (ROC) analysis for Progression-Free (PFS) and Overall Survival (OS) 
for conventional and heterogeneity positron emission tomography (PET) parameters.
Parameter for AUC 95% CI Sensitivity (%)
Specificity 



































































Coefficient of Variation PFS 0.53 0.44-0.61 48 64 >0.3559 0.58OS 0.53 0.45-0.62 28 90 >0.4794 0.55
Skewness PFS 0.52 0.435-0.607 28 88 >0.8465 0.66OS 0.52 0.44-0.6 35 87 >0.8465 0.71
Entropy PFS 0.60 0.52-0.68 37 83 ≤5.6443 0.04*OS 0.70 0.61-0.77 65 74 ≤6.1767 0.0001*
Homogeneity PFS 0.61 0.51-0.68 39 88 >0.0175 0.020*
OS 0.67 0.62-0.78 61 78 >0.0118 0.0004*
Correlation
PFS 0.64 0.55-0.72 42 86 ≤0.1581 0.004*
OS 0.69 0.6-0.77 70 68 ≤0.4184 0.0001*
Contrast PFS 0.51 0.42-0.60 32 81 ≤10433 0.84
OS 0.54 0.46-0.26 35 82 ≤5186.45 0.51
Short Zone 
Emphasis
PFS 0.60 0.52-0.69 56 64 >0.9998 0.031*
OS 0.62 0.53-0.70 53 78 >0.9999 0.024*
Size Variation PFS 0.59 0.5-0.68 43 83 >0.0004 0.06
OS 0.70 0.56.0.72 44 82 ≤1976.855 <0.0001*
As obtained by Cox multiparametric analysis, only the above-mentioned heterogeneity parameters were independent from 
each other. Of the whole cohort (n=141), 75 patients demonstrated progressive disease, 54 died. Compared to conventional 
parameters, heterogeneity parameters (such as Entropy, Homogeneity, Correlation, Short Zone Emphasis, Size Variation) 
demonstrated higher AUC values. Additionally, these imaging-based features reached a statistically significant distinction 
between responders and non-responders. * = statistically significant, # = independent according to Cox analysis. CI = 





In the present study, we investigated the prognostic 
value of PET-assessed tumor heterogeneity in patients 
scheduled for PRRT. Several textural characteristics like 
Entropy, Skewness, Correlation, Short Zone Emphasis and 
Homogeneity demonstrated superior diagnostic capability 
than standard PET parameters such as mean and maximum 
standardized uptake value (SUVmax / SUVmean). 
Several studies have reported the feasibility of 
texture analysis for heterogeneity assessment and its 
prognostic implication for individual patient outcome 
based on pretherapeutic CT and magnetic resonance 
imaging, e.g. in non-small cell lung carcinoma or prostate 
cancer [13-15]. Due to its ability to visualize whole-body 
tumor burden on a molecular level, PET-based tumor 
heterogeneity offers certain advantages for assessing 
intraindividual heterogeneity patterns in tumor biology. 
Consequently, prognostic capability of imaging-derived 
intratumoral heterogeneity using 18F-FDG but also SSTR-
PET/CT has been evaluated in several tumor entities, such 
as breast, rectal, thyroid or esophageal cancer [4, 6, 16-
18]. In NET, given the complexity of various diagnostic 
procedures and treatment options, early identification 
of subjects likely to benefit from PRRT would be of 
great value for individualized treatment tailoring. As 
demonstrated in the present study, application of textural 
parameters could be helpful in differentiating high-risk 
from low-risk groups during PRRT. Strikingly, the 4 
parameters Entropy, Correlation, Short Zone Emphasis 
and Homogeneity provided a significant distinction 
Figure 1: Kaplan-Meier plots and number-at-risk tables for probability of Progression-Free Survival (n  =  139). Low-
risk group (solid lines) was identified by various textural parameters measured on somatostatin receptor positron emission tomography/
computed tomography (PET/CT) before Peptide Receptor Radionuclide Therapy. Cut-off values derived by Receiver operating 
characteristics analysis were used. d = days.
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between responders from non-responders (Table 3, Figure 
1 and 2).
In NET, conventional CT-derived therapy response 
assessment failed to predict disease-related progression 
or survival [19, 20]. Regarding functional imaging, data 
is unequivocal: On the one hand, increasing uptake in 
SSTR scintigraphy (Octreoscan®) was reported as a 
significant predictor of PFS [21, 22]. On the other hand, 
conventional PET parameters like SUVmax failed to predict 
time-to progression in SSTR-expressing tumor entities 
[23]. In line with this finding, Gabriel and colleagues 
also demonstrated no benefit from conventional 68Ga-
DOTATOC PET parameters neither for response nor 
survival prediction in GEP NET patients scheduled for 
PRRT [24]. 
By contrast, heterogeneity parameters demonstrated 
prognostic value in this study, thereby, outperforming most 
conventional PET parameters. Of note, only the standard 
feature TRE proved useful in terms of OS prediction. 
Not surprisingly, the cumulative treatment dose 
correlated significantly with both PFS and OS. This could 
be regarded as a kind of intra-observer quality control of 
our study: with increasing progression-free and overall 
survival, more treatment cycles are performed and, 
consequently, the administered dose rises. 
Interestingly, well-established histology or serum-
based parameters of tumor aggressiveness or burden, such 
as the proliferation index Ki67 (PFS, p = 0.09) or CgA 
(OS, p = 0.06), failed to reach prognostic significance. 
This finding might be influenced by sampling bias: 
Couvelard and colleagues showed that two randomly taken 
cores from the same metastasis of pancreatic NETs led to 
Figure 2: Kaplan-Meier plots and number-at-risk tables for probability of Overall Survival (n  =  141).  Low-risk group 
(solid lines) was identified by various textural parameters measured on somatostatin receptor positron emission tomography/computed 
tomography (PET/CT) before Peptide Receptor Radionuclide Therapy. Cut-off values derived by Receiver operating characteristics 
analysis were used. d = days.
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Figure 3.2: Schematic example of Entropy assessment as one of the heterogeneity parameters. Baseline somatostatin 
receptor positron emission tomography of a subject suffering from liver metastasis of a gastroenteric neuroendocrine tumor. Magnification 
of a liver metastasis demonstrates intralesional differences in 68Ga-DOTA-D-Phe-Tyr3-octreotate (68Ga-DOTATATE) distribution. For 
calculation of Entropy as a second order textural parameter the activity values in the lesion are discretized and a spatial dependence 
matrix (M1) is created. M1 determines how often a pixel with intensity i finds itself within a certain relationship (e.g. next neighbor in one 
direction) to another pixel with intensity j in a volume of interest [28].
Figure 3.1: Baseline somatostatin receptor (SSTR) positron emission tomography/computed tomography (PET/CT) 
of a 24-year old male suffering from metastatic ileum neuroendocrine tumor. Liver metastasis can be detected on CT (A) and 
on SSTR-PET/CT (B) indicated by the arrows. Manual stepwise segmentation of the lesion (arrow) by a region of interest on the PET-only 
images was performed (C). An overview of investigated heterogeneity parameters can be found in [26, 27], Table 4 and Figure 3.2.
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a change in grading in half of the cases [25]. Therefore, 
especially in patients with multiple lesions, non-invasive 
and reliable whole-body assessment of intra-tumor 
heterogeneity might yield completely different results [29] 
and contribute to individualised treatment decisions [30]. 
Diagnostic imaging of NET is the domain of 
SSTR agonists as well as 18F-FDG PET/CT in case of 
dedifferentiation [31]. More recently, specific ligands 
targeting C-X-C motif chemokine receptor 4 (CXCR4) for 
diagnostic and therapeutic purposes were also introduced 
[32-37] and in the future, a combination of these above-
mentioned radionuclides might also potentially offer 
additional insight in NET biology and its underlying 
heterogeneity. 
This study has several limitations: As disadvantage 
of a large multicentric trial, imaging as well as therapeutic 
protocols might differ from center to center. Especially 
when dealing with elaborated image analysis as textural 
features, varieties due to different PET/CT machines and 
different acquisition protocols may occur. However, using 
18F-FDG, Tixier et al. proved robustness of certain local 
or regional characterization features (e.g. Entropy), which 
also reached significance in our analysis [38]. Moreover, 
we are aware of the multiple testing problem; however, 
even when we correct for alpha inflation, the majority of 
tests remain significant.
Though NET is a rare disease with an annual 
incidence of approximately 5 new cases per 100.000 
inhabitants [1], we were able to enroll a cohort of more 
than 140 patients which underwent PRRT. Therefore, 
advantages for such a multicentric trial might overcome 
the disadvantage of different diagnostic or therapeutic 
protocols. Also the low incidence of this disease 
complicates prospective reproduction of such analysis, 
which would be still the next step to achieve more 
standardized results.
In conclusion, in this multicenter trial enrolling 
141 patients, tumor heterogeneity as assessed by baseline 
SSTR-PET/CT proved prognostic value in PRRT 
candidates and outperformed common conventional PET 
parameters. Assessment of intratumoral heterogeneity 
might significantly contribute to a more individualized 
Table 3: Results of Kaplan-Meier analysis regarding for Progression-Free (PFS) and Overall Survival (OS).
Parameter for x2 p-value HR negative CI HR positive CI
Entropy PFS 7.14 0.007 1.87 1.09-3.19 0.54 0.31-0.92OS 14.45 0.0001 2.79 1.62-4.81 0.36 0.21-0.62
Correlation PFS 7.85 0.005 1.9 1.14-3.16 0.53 0.32-0.88OS 11.31 0.0008 2.61 1.53-4.45 0.38 0.23-0.65
Short Zone Emphasis PFS 7.99 0.004 1.87 1.17-3.0 0.53 0.33-0.85OS 12.91 0.0003 2.53 1.39-4.62 0.4 0.22-0.72
Homogeneity PFS 3.71 0.05 1.58 1.0-2.49 0.63 0.4-1.0
OS 5.41 0.01 1.86 1.04-3.33 0.54 0.3-0.96
TRE OS 10.39 0.001 2.34 1.25-4.36 0.43 0.23-0.80
Whole cohort (n = 141), 75 demonstrated progressive disease, 54 died. CI = confidence interval, HR = Hazard Ratio, TRE = 
tissue receptor expression (as a conventional positron emission tomography parameter).
Table 4: Overview of selected textural parameters. 
Parameter Order Description
Coefficient of Variation (COV) 1st A normalized measure of dispersion of a frequency distribution. 
Skewness 1st A measure for the extent to which a frequency distribution “leans” to side of the mean value of the distribution.
Entropy 2st Measures grade of derangement, e.g. a homogenous matrix demonstrates low entropy.
Homogeneity 2st A measure for continuous areas of same or similar voxel values in an image or voxel of interest (VOI).
Correlation 2st A measure of intensity linear-dependencies.
Contrast 2st Measures the difference of the grey value when going to the next voxel. It is high when the intensity changes very often between single voxels.
Short Zone Emphasis 3st Measures the distribution of short zones. It is highly dependent on the occurrence of small zones and is expected to be large for fine textures.
Size Variation 3st Describes the variation in the size of different substructures in an image (VOI).
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patient management and treatment tailoring.
MATERIALS AND METHODS
All patients gave written and informed consent to 
the treatment and imaging procedures. The study was 
approved by local institutional review boards or the 
requirement for additional approval was waived due to the 
retrospective character of this study. 
Patient population
In a retrospective cohort, 142 patients (71/141 
females (50.4%), 63 ± 11 years, median 64 y, range, 24-
83 y) at the four university hospitals of Bonn (n = 78), 
Wuerzburg (n = 27), Munich (n = 21) and Hannover (n 
= 15) were enrolled. Gastroenteropancreatic (GEP)-NET 
(including primary tumors of the pancreas, stomach, 
ileum/jejunum/mesenterium and colon) occurred in 
108/141 (76.6%) patients, 15/141 (10.6%) were classified 
as cancer of unknown primary (CUP), 9/141 (6.4%) had 
lung NET and the remaining 9 patients (6.4%) suffered 
from other tumor entities (including meningeoma, 
hemangioendothelioma, pheochromocytoma, medullary 
thyroid carcinoma and pituitary tumor). Histological 
confirmation of the diagnosis was available in every 
patient. Proliferation index Ki67 ranged between 1-40% 
with a median of 5%. Chromogranin A (CgA) levels prior 
to therapy ranged between 35 - 64700 µg/l (median, 571 
µg/l). All patients had undergone a number of previous 
treatments including surgery (n = 76/141, 53.9%), 
sandostatin therapy (n = 79/141, 56%), chemotherapy (n 
= 39/141, 27.7%), or external beam radiation therapy (n = 
15/141, 10.6%). 
Clinical and routinely acquired characteristics of 
the patient cohort including sex, age, prior therapies, site 
of metastases, CgA, Ki67, and administered activities are 
given in Table 1.
Radiopeptide therapy was performed according to 
the Rotterdam protocol as outlined by Kwekkeboom et al. 
as well as The joint IAEA, EANM and SNMMI practical 
guidance on a compassionate use basis, respectively [11, 
19]. A total of 709 treatment cycles (median, 4, range, 
1-6) with a median of 7.3 Gigabecquerel (GBq) (range, 
0.9-9.0 GBq) per cycle with 177Lutetium (177Lu)-labeled 
somatostatin analog (177Lu-DOTATATE/- DOTA-D-
Phe-Tyr3-octreotide (DOTATOC)) were performed. 
Imaging including both functional (SSTR-PET/CT) and/
or morphologic imaging (CT) modalities was conducted 
every 3-6 months after PRRT [11]. PFS was defined 
according to Response Evaluation Criteria in Solid Tumors 
1.1 (RECIST 1.1) by serial radiological assessment 
starting from the time point of baseline imaging and/or 
according to clinical signs of progression [11, 39. For 
the calculation of overall survival (OS) the time interval 
between the pre-therapeutic PET examination and the date 
of death was used. 
PET/CT imaging
Prior to PRRT, all patients underwent SSTR-PET/
CT according to EANM guidelines to assess tumor 
receptor expression [11]. A median of 124 Megabecquerel 
(MBq) (range, 61-239 MBq) of 68Ga-DOTATATE/-
TOC was injected intravenously. After 60 minutes, 
imaging was performed using the following devices: 
Bonn, Biograph 2 PET/CT (Siemens Medical Solutions, 
Erlangen, Germany); Wuerzburg, Biograph 64 (Siemens 
Medical Solutions, Erlangen, Germany); Munich, Gemini 
TF PET/CT (Philips Medical, Eindhoven, Netherlands) 
or Siemens Biograph 64 (Siemens Medical Solutions, 
Erlangen, Germany); Hannover, Biograph 2 (Siemens 
Medical Solutions, Erlangen, Germany). All data was 
reconstructed using iterative algorithms implemented by 
the manufacturer and depending on the routine protocol 
of the different medical centers. Scatter and attenuation 
correction was performed based on the different 
transmission data.
Image interpretation
Analysis of the dataset was performed at the 
university hospitals of Bonn and Wuerzburg. All 
image data were transferred to an Interview Fusion 
Workstation (Mediso Medical Imaging Systems Ltd., 
Budapest, Hungary). Conventional parameters (such 
as SUVmean/SUVmax , TRE)) were derived. TRE is the 
product of segmented lesion volume times the mean 
activity uptake, analog to the total lesion glycolysis in 
18F-fluorodeoxyglucose (18F-FDG) PET. For analysis 
of tumor heterogeneity the largest lymph node, bone 
and visceral metastases were assessed. For system-
based analysis the mean value of these lesions for each 
individual system was used. For patient-based analysis, 
the mean value of all segmented lesions per patient 
was performed. Metastases smaller than 15 mm were 
not taken into account to avoid partial volume effects. 
Manual segmentation was executed in combined PET/
CT data (Figure 3.1). Several different textural parameters 
representing intratumoral heterogeneity were derived from 
every individual lesion and were divided in first order 
parameters (e.g., Coefficient of variation, COV), second 
order parameters (e.g., Entropy, Correlation) and higher 
order parameters (e.g., Grey Level Uniformity, Intensity 
Variation, Short Zone Emphasis). A detailed description 
can be found in Table 4, Figure 3.2, [26] and [27]. For 
comparison to heterogeneity parameters, conventional 
diagnostic parameters were evaluated: morphologic 
volume of the lesion, maximum standardized uptake value 
(SUVmax), mean SUV (SUVmean), and TRE were assessed. 
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The SUV was calculated according to the body weight of 
the patient. In total, 872 lesions (median, 6, range, 1-23 
per patient) were manually segmented. 
Statistical analysis
First, Cox multiparametric regression was applied to 
determine independent prognostic parameters of PFS and 
OS as well as estimation of HR. Due to multi-colinearity 
of different textural parameters, only the following 
parameters were included in the final Cox regression: 
COV, Skewness, Entropy, Homogeneity, Correlation, 
Contrast, Short Zone Emphasis and Size Variation. For 
all independent parameters, ROC analysis was obtained 
to estimate the optimal cut-off value for the individual 
parameters to assess progress and OS in the follow-up 
period. For this purpose, the Youden index was used to 
maximize the sum of sensitivity and specificity [40]. The 
area under curve (AUC) was calculated including the 
exact binominal confidence intervals (95% confidence 
level). Statistical significance of the prognostic capability 
was assumed when the critical value of 0.5 was not 
included in the confidence interval. For the parameters 
showing such significance, the relationship to both PFS 
and OS was analyzed using Kaplan-Meier plots. Kaplan-
Meier analysis was performed using thresholds established 
by prior ROC analysis. Differences between Kaplan-Meier 
curves were evaluated using nonparametric log-rank tests, 
considering differences with a p value smaller than 0.05 
to be significant. 
Cox analysis was executed using the software 
package R (version 3.2.4, www.r-project.org). ROC 
analysis and Kaplan-Meier analysis was performed 
using MedCalc software (version 12.3.0.0, MedCalc 
Mariakerke, Belgium). 
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